New York, USA, June 08, 2022 (GLOBE NEWSWIRE) -- Advanced Cervical Cancer Clinical Trial Pipeline Analysis Research Report 2022 by DelveInsight
As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a significant unmet medical need. Advanced Cervical Cancer Pipeline involves 75+ key companies continuously working towards developing 75+ Advanced Cervical Cancer treatment therapies.
DelveInsight’s 'Advanced Cervical Cancer Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline Advanced Cervical Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Cervical Cancer pipeline domain.
Key Takeaways from the Advanced Cervical Cancer Pipeline Report
- DelveInsight’s Advanced Cervical Cancer Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
- The leading Advanced Cervical Cancer companies such as Akeso Biopharma, Hookipa Biotech GmbH, Biocad, Shanghai Henlius Biotech, Genexine, Inc., GlaxoSmithKline, EMD Serono, Zeria Pharmaceutical, Agenus Inc., Corregene Biotechnology Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nykode Therapeutics, Instil Bio, Fujifilm Pharmaceuticals U.S.A., Inc., Nurix Therapeutics, Inc., Bristol-Myers Squibb, NETRIS Pharma, Suzhou BlueHorse Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Adlai Nortye Biopharma Co., Ltd., SOTIO, Astex Pharmaceuticals, Inc., Rubius Therapeutics, Seagen Inc., Kymab Limited, Incyte Corporation, Ocellaris Pharma, Inc., NGM Biopharmaceuticals, Inc., Nurix Therapeutics, Inc., Andes Biotechnologies, Arcus Biosciences, Inc., AstraZeneca, OncoC4, Inc., Turnstone Biologics, Corp., Nanobiotix, HiFiBiO Therapeutics, Corvus Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Prelude Therapeutics, Medicenna Therapeutics, Inc., Tarveda Therapeutics, Synthekine, RAPT Therapeutics, Inc., Shattuck Labs, Inc., BioAtla, Inc., Quadriga Biosciences, Inc., Klus Pharma Inc., Exelixis, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd., Genentech, Qilu Pharmaceutical Co., Ltd., Lee's Pharmaceutical Limited, Guangzhou Gloria Biosciences Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., ISA Pharmaceuticals B.V., Agenus Inc., Cellid Co., Ltd., Advenchen Laboratories, LLC, TCRCure Biopharma Ltd., Iovance Biotherapeutics, Inc., MacroGenics, Transgene, Nanobiotix, Antengene Corporation, and others are developing novel drug candidates to improve the Advanced Cervical Cancer treatment landscape.
- Key Advanced Cervical Cancer pipeline therapies in various stages of development include AK104, HB-201, BCD-100, HLX10, GX-188E, TSR-042, M7824, Z-100, CRTE7A2-01, TQ-B3525, VB10.16, Bintrafusp alfa, ITIL-168, FF-10850, De-TIL-0255, BMS-986340, NP137, LM 103, SG001, AK112, XmAb20717, SO-C101, AN0025, ASTX660, RTX-321, SGN-ALPV, KY1044, SGN-B6A, INCB099318, OC-001, NGM707, NX-1607, Andes-1537, AB308, AZD8701, ONC-392, TBio-6517, NBTXR3, SEA-TGT, HFB200301, CPI-006, NGM438, PRT1419, MDNA11, PEN-866, tucatinib, STK-012, FLX475, SL-279252, BA3071, QBS10072S, A166, XB002, TQB2450, SHR-1210, GB226, Atezolizumab, QL1604, ZKAB001, GLS-010, SHR-1701, ISA101b, SG001, AGEN1884, BVAC-C, AL3818, TC-E202 cells, LN-145, NP137, SO-C101, XmAb20717, MGD013, TG4001, QBS10072S, NBTXR3, ATG-008, and others.
- In June 2022, Antengene Corporation Limited announced that an abstract titled "A phase I/II study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)" will be presented as a poster during the 2022 American Society of Clinical Oncology (ASCO 2022), taking place from June 3rd to 7th in Chicago, Illinois via in-person or virtual attendance.
- In May 2022, Nykode Therapeutics AS announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients with HPV16-positive advanced cervical cancer. Interim results from 39 patients with a median follow-up of 6 months show an ORR of 21%—including two patients who achieved a complete response and six who achieved a partial response—and a very high disease control rate of 64%. The trial enrolled a heavily pre-treated patient population, with more than two-thirds of the patients having received at least two previous systemic lines of treatment.
- In May 2022, NGM Biopharmaceuticals, Inc. (NGM Bio) announced it had initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. The trial will enroll up to approximately 80 adult patients with multiple tumor types, including pancreatic cancer, breast cancer, mesothelioma, gastric cancer, non-small cell lung cancer (NSCLC), cervical and endocervical cancer, biliary duct cancer (cholangiocarcinoma), squamous cell carcinoma of the head and neck (SCCHN), urothelial bladder cancer, colorectal cancer (CRC), esophageal cancer, ovarian cancer, renal cell carcinoma (RCC), prostate cancer and melanoma (skin cutaneous).
- In April 2022, Nurix Therapeutics, Inc. announced that the first patient had been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor-infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio. The trial is designed to evaluate the safety and efficacy of DeTIL-0255 in patients with advanced gynecological malignancies, including ovarian cancer, cervical cancer, and endometrial cancer.
- In November 2021, TCRCure announced that they had received Investigational New Drug (IND) approval from the CENTER FOR DRUG EVALUATION, NMPA (the “CDE”)for the Phase 1/2 clinical study of Modified autologous T cells for targeting HPV and delivery of anti-PD-1 in the treatment of HPV-positive recurrence and metastasis cervical cancer.
Request a sample and discover the recent breakthroughs and advances in treating Advanced Cervical Cancer @ Advanced Cervical Cancer Pipeline Outlook
The Advanced Cervical Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Cervical Cancer drugs products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Cervical Cancer pipeline landscape.
Advanced Cervical Cancer Overview
Advanced Cervical Cancer indicates that the disease has spread from the cervix to another body part, such as the lungs. Cancer is sometimes advanced when it is discovered. Unfortunately, advanced cancer is typically incurable. However, treatment may control it, alleviate symptoms of Advanced Cervical Cancer, and enhance the quality of life for a while. The lymph nodes, liver, lungs, and bones are the most prevalent sites for cervical cancer spread. The common Advanced Cervical Cancer symptoms include vaginal bleeding after intercourse, between periods or after menopause, watery, bloody vaginal discharge that may be heavy and have a foul odor, pelvic pain or pain during intercourse, and others. The Advanced Cervical Cancer life expectancy is generally 5 years in patients with stage III or IVA cervical cancer. The complications of Advanced Cervical cancer can range from the seemingly modest, such as minor vaginal bleeding or frequently urinating, to the potentially fatal, such as severe bleeding or kidney failure.
Advanced Cervical Cancer treatment is determined by the size and location of the tumor in the body. Chemotherapy can be used for Advanced Cervical Cancer treatment. Some women may have a procedure termed pelvic exenteration for cervical cancer that has returned within the pelvis.
Find out more about immunotherapy for Advanced or Relapsed Cervical Cancer@ Advanced Cervical Cancer Therapy
A snapshot of the Advanced Cervical Cancer Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| AK104 | Akeso Biopharma | Preregistration | Programmed cell death-1 receptor antagonist | Intravenous |
| Z-100 | Zeria Pharmaceutical | Phase III | Immunomodulator | Subcutaneous |
| TQ-B3525 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase II | Phosphatidylinositol 3 kinase delta inhibitor | Oral |
| VB10.16 | Nykode Therapeutics AS | Phase II | Antigen presenting cell modulator | Intramuscular |
| XmAb20717 | Xencor, Inc. | Phase II | Programmed cell death-1 ligand-1 inhibitor | Intravenous |
| DeTIL-0255 | Nurix Therapeutics, Inc. | Phase I | T lymphocyte replacement | Parenteral |
| HFB200301 | HiFiBiO Therapeutics | Phase I | CD4-positive T lymphocyte stimulant | Intravenous |
| NX-1607 | Nurix Therapeutics, Inc. | Phase I | CBLB protein expression inhibitor | Oral |
Learn more about the novel and emerging Advanced Cervical Cancer pipeline therapies @ Advanced Cervical Cancer Clinical Trials
Advanced Cervical Cancer Therapeutics Assessment
The Advanced Cervical Cancer Pipeline report proffers an integral view of the Advanced Cervical Canceremerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Advanced Cervical Cancer Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
- Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
- Therapeutics Assessment By Mechanism of Action: Programmed cell death-1 ligand-1 inhibitors, T lymphocyte stimulants, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, TNF related apoptosis inducing ligand stimulants, TRAIL receptor 1 agonists, Immunostimulants
- Key Advanced Cervical Cancer Companies: Akeso Biopharma, Hookipa Biotech GmbH, Biocad, Shanghai Henlius Biotech, Genexine, Inc., GlaxoSmithKline, EMD Serono, Zeria Pharmaceutical, Agenus Inc., Corregene Biotechnology Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nykode Therapeutics, Instil Bio, Fujifilm Pharmaceuticals U.S.A., Inc., Nurix Therapeutics, Inc., Bristol-Myers Squibb, NETRIS Pharma, Suzhou BlueHorse Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Adlai Nortye Biopharma Co., Ltd., SOTIO, Astex Pharmaceuticals, Inc., Rubius Therapeutics, Seagen Inc., Kymab Limited, Incyte Corporation, Ocellaris Pharma, Inc., NGM Biopharmaceuticals, Inc., Nurix Therapeutics, Inc., Andes Biotechnologies, Arcus Biosciences, Inc., AstraZeneca, OncoC4, Inc., Turnstone Biologics, Corp., Nanobiotix, HiFiBiO Therapeutics, Corvus Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Prelude Therapeutics, Medicenna Therapeutics, Inc., Tarveda Therapeutics, Synthekine, RAPT Therapeutics, Inc., Shattuck Labs, Inc., BioAtla, Inc., Quadriga Biosciences, Inc., Klus Pharma Inc., Exelixis, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd., Genentech, Qilu Pharmaceutical Co., Ltd., Lee's Pharmaceutical Limited, Guangzhou Gloria Biosciences Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., ISA Pharmaceuticals B.V., Agenus Inc., Cellid Co., Ltd., Advenchen Laboratories, LLC, TCRCure Biopharma Ltd., Iovance Biotherapeutics, Inc., MacroGenics, Transgene, Nanobiotix, Antengene Corporation, and others
- Key Advanced Cervical Cancer Pipeline Therapies: AK104, HB-201, BCD-100, HLX10, GX-188E, TSR-042, M7824, Z-100, CRTE7A2-01, TQ-B3525, VB10.16, Bintrafusp alfa, ITIL-168, FF-10850, De-TIL-0255, BMS-986340, NP137, LM 103, SG001, AK112, XmAb20717, SO-C101, AN0025, ASTX660, RTX-321, SGN-ALPV, KY1044, SGN-B6A, INCB099318, OC-001, NGM707, NX-1607, Andes-1537, AB308, AZD8701, ONC-392, TBio-6517, NBTXR3, SEA-TGT, HFB200301, CPI-006, NGM438, PRT1419, MDNA11, PEN-866, tucatinib, STK-012, FLX475, SL-279252, BA3071, QBS10072S, A166, XB002, TQB2450, SHR-1210, GB226, Atezolizumab, QL1604, ZKAB001, GLS-010, SHR-1701, ISA101b, SG001, AGEN1884, BVAC-C, AL3818, TC-E202 cells, LN-145, NP137, SO-C101, XmAb20717, MGD013, TG4001, QBS10072S, NBTXR3, ATG-008, and others.
Dive deep into rich insights into new Advanced Cervical Cancer drugs, visit @ Advanced Cervical Cancer Treatment
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Advanced Cervical Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Advanced Cervical Cancer Pipeline Therapeutics |
| 6. | Advanced Cervical Cancer Pipeline: Late Stage Products (Phase III) |
| 6.1 | Z-100: Zeria Pharmaceutical |
| 7. | Advanced Cervical Cancer Pipeline: Mid Stage Products (Phase II) |
| 7.1 | TQ-B3525: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 8. | Advanced Cervical Cancer Pipeline: Early Stage Products (Phase I) |
| 8.1 | HFB200301: HiFiBiO Therapeutics |
| 8.2 | NX-1607: Nurix Therapeutics, Inc. |
| 9. | Advanced Cervical Cancer Pipeline: Preclinical Stage Products |
| 10. | Advanced Cervical Cancer Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Advanced Cervical Cancer Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies in the Advanced Cervical Cancer Pipeline |
| 14. | Key Products in the Advanced Cervical Cancer Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Advanced Cervical Cancer pipeline therapeutics, reach out @ Advanced Cervical Cancer Drugs
Related Reports
Cervical Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cervical Cancer companies including Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, among others.
Cervical Cancer Epidemiology Forecast
Cervical Cancer Epidemiology Forecast–2032 report delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology, and the Cervical Cancer epidemiology trends.
Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Cervical Cancer companies including Henlix Biotech, Zeria, Advaxis, among others.
Advanced Ovarian Cancer Pipeline
Advanced Ovarian Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Advanced Ovarian Cancer companies including ImmunoGen, OncoQuest, Lee's Pharmaceutical, among others.
Advanced Urothelial Carcinoma Pipeline
Advanced Urothelial Carcinoma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Advanced Urothelial Carcinoma companies including Bayer, Mirati Therapeutics, among others.
Advanced Gastric Carcinoma Pipeline
Advanced Gastric Carcinoma Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Advanced Gastric Carcinoma companies including Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, among others.
Other Trending Reports
Glomerulonephritis Market | Lymphedema Market | Audiology Devices Market | Campylobacter Infections Market | Varicose Veins Market | Nasolabial Fold Market | Reactive Airway Disease Market | Scleritis Market | Contrast-Induced Nephropathy Market
Related Healthcare Blogs
Cervical Cancer Market Outlook
Usage of HPV Vaccine in Cervical Cancers
Preventing Cervical Cancer Through Screening
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us at LinkedIn |Facebook |Twitter
